Lenalidomide induced good clinical response in a patient with multiple relapsed and refractory Hodgkin's lymphoma - PubMed (original) (raw)

Case Reports

Lenalidomide induced good clinical response in a patient with multiple relapsed and refractory Hodgkin's lymphoma

Inga Mandac et al. J Hematol Oncol. 2010.

Abstract

Background: A 24-year-old female patient was diagnosed with classic Hodgkin's lymphoma in clinical stage II, and combination chemotherapy followed by radiotherapy was initiated. During the following 5 years, the disease progressed despite several standard therapeutic approaches, including autologous and allogeneic stem cell transplantation.

Methods: Lenalidomide (25 mg daily) treatment was then initiated in a continuous dosing schedule. Positron emission tomography scans were performed before and during lenalidomide treatment. Hematologic and laboratory values, as well as physical condition were also assessed before and during lenalidomide treatment.

Results: Four months after continuous lenalidomide treatment, tumor load was significantly reduced, B symptoms had resolved, and the patient's physical condition had improved, allowing her to resume normal daily-living activities. Evaluations after 15 months of lenalidomide treatment indicated limited disease progression. Nevertheless, the patient was feeling well and maintaining a normal active life. Treatment was well tolerated, allowing the patient to remain on continuous dosing, which has now been maintained for 18 months.

Conclusion: Daily, long-term lenalidomide treatment provided clinical benefit and was well tolerated in a patient with relapsed, advanced classic Hodgkin's lymphoma.

PubMed Disclaimer

Figures

Figure 1

Positron emission tomography scans. (A) Before treatment with lenalidomide; (B) after 4 months of continuous lenalidomide treatment; and (C) after 15 months of continuous lenalidomide treatment.

Cited by

Complete response associated with lenalidomide and celecoxib in a case of primary refractory Hodgkin lymphoma.
Garcia-Recio M, Martinez-Serra J, Mestre F, Bento L, Gines J, Ramos R, Daumal J, López P, Sampol A, Gutierrez A. Garcia-Recio M, et al. Onco Targets Ther. 2018 Oct 8;11:6599-6603. doi: 10.2147/OTT.S175016. eCollection 2018. Onco Targets Ther. 2018. PMID: 30349293 Free PMC article.
Low dose continuous lenalidomide in heavily pretreated patients with relapsed or refractory classical Hodgkin lymphoma: a retrospective case series.
Ma H, Cheng B, Montanari F, Lue JK, Deng C, Marchi E, O' Connor OA, Sawas A. Ma H, et al. Ther Adv Hematol. 2020 Sep 26;11:2040620720947340. doi: 10.1177/2040620720947340. eCollection 2020. Ther Adv Hematol. 2020. PMID: 33062232 Free PMC article.
Recombinant human endostatin enhances the radioresponse in esophageal squamous cell carcinoma by normalizing tumor vasculature and reducing hypoxia.
Zhu H, Yang X, Ding Y, Liu J, Lu J, Zhan L, Qin Q, Zhang H, Chen X, Yang Y, Yang Y, Liu Z, Yang M, Zhou X, Cheng H, Sun X. Zhu H, et al. Sci Rep. 2015 Sep 28;5:14503. doi: 10.1038/srep14503. Sci Rep. 2015. PMID: 26412785 Free PMC article.
Lenalidomide with or without dexamethasone for relapsed or refractory Hodgkin lymphoma post autologous stem cell transplant.
Kumbhalwar K, Punatar S, Gokarn A, Nayak L, Chichra A, Mirgh S, Jindal N, Mathew L, Khattry N. Kumbhalwar K, et al. Blood Cell Ther. 2023 Aug 25;6(3):95-103. doi: 10.31547/bct-2023-009. eCollection 2023 Aug 25. Blood Cell Ther. 2023. PMID: 38146353 Free PMC article.

References

1. Wiernik PH, Lossos IS, Tuscano JM, Justice G, Vose JM, Cole CE, Lam W, McBride K, Wride K, Pietronigro D, Takeshita K, Ervin-Haynes A, Zeldis JB, Habermann TM. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2008;26:4952–4957. doi: 10.1200/JCO.2007.15.3429. - DOI - PubMed
1. Witzig TE, Wiernik PH, Moore T, Reeder C, Cole C, Justice G, Kaplan H, Voralia M, Pietronigro D, Takeshita K, Ervin-Haynes A, Zeldis JB, Vose JM. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's lymphoma. J Clin Oncol. 2009;27:5404–5409. doi: 10.1200/JCO.2008.21.1169. - DOI - PubMed
1. Fehniger TA, Larson S, Trinkhaus K, Siegel MJ, Cashen AF, Blum KA, Fenske TS, Hurd DD, Goy A, DiPersio JF, Bartlett NL. A phase II multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma [abstract] http://ash.confex.com/ash/2009/webprogram/Paper18377.html - PMC - PubMed
1. Böll B, Borchmann P, Topp MS, Hänel M, Reiners KS, Engert A, Naumann R. Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma. Br J Haematol. 2010;148:480–482. doi: 10.1111/j.1365-2141.2009.07963.x. - DOI - PubMed

Lenalidomide induced good clinical response in a patient with multiple relapsed and refractory Hodgkin's lymphoma - PubMed (original) (raw)